Al-Mahzoum Kholoud, Abdelaziz Doaa H, Alenezi Fajer, Almutairi Jouza, Alsubaiei Mohammad Khaled, Alharbi Abdullah Bader, Al-Rawi Sarah, Al-Rawi Shahad, Bousheheri Fatemah Faisal, Alhajri Ahmad Hameed, Alajmi Saif Nasser, Sallam Mohammed, Mansour Noha O, Alnazly Eman Khamis, Sallam Malik
Sheikh Jaber Al-Ahmad Al-Sabah Hospital, Ministry of Health, Kuwait City, Kuwait.
Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Baha University, Al-Baha, Saudi Arabia.
Diabetes Metab Syndr Obes. 2025 May 3;18:1389-1409. doi: 10.2147/DMSO.S518994. eCollection 2025.
Glucagon-like peptide-1 (GLP-1) receptor agonists including Mounjaro and Ozempic, are increasingly used for weight management. Assessing the attitudes and beliefs of current and future healthcare professionals is important considering their roles in recommending and prescribing these drugs. This study aimed to investigate the attitudes toward Mounjaro and Ozempic and its correlation with obesity/overweight bias among healthcare professionals and students in medicine and pharmacy in Arab countries.
This cross-sectional study was based on a self-administered online questionnaire with participants recruited via a convenient snowball sampling approach. Attitudes towards Mounjaro and Ozempic were evaluated using a newly developed construct termed Mini Health Beliefs and Attitudes toward GLP-1 Drugs Scale (mini-HBAGS), alongside a novel scale to assess obesity/overweight bias (OOB). The new constructs' validity was assessed via content validity, principal component analysis (PCA), and Cronbach's α.
The study included 413 participants predominantly from Kuwait (32.8%), Egypt (20.9%), Saudi Arabia (18.8%), and Jordan (15.4%). Familiarity with Mounjaro and Ozempic was high (83.6%), with 17.2% recommending them. Weight management drug use was 14.0%, including 5.9% for Mounjaro and Ozempic. Among participants familiar with Mounjaro and Ozempic, the mean OOB score was 3.83±0.62 (range: 1.00-5.00), indicating agreement, while the mean score for the mini-H-BAGS was 2.70±0.716 (range: 1.00-5.00), indicating a slightly unfavorable attitude. PCA identified perceived benefits and barriers, and subjective norms and attitudes, as key determinants of attitudes toward Mounjaro and Ozempic.
This study revealed slightly negative attitudes toward Mounjaro and Ozempic among healthcare professionals and students in Arab countries. The negative attitudes observed likely reflect concerns about side effects, cost, and accessibility of these medications. The findings highlighted the need for targeted education in Arab countries to address obesity bias and encourage a balanced evaluation of the benefits and risks of GLP-1 drugs for weight management.
包括Mounjaro和Ozempic在内的胰高血糖素样肽-1（GLP-1）受体激动剂越来越多地用于体重管理。鉴于当前和未来医疗保健专业人员在推荐和开这些药物方面的作用，评估他们的态度和信念很重要。本研究旨在调查阿拉伯国家医学和药学专业的医疗保健专业人员及学生对Mounjaro和Ozempic的态度及其与肥胖/超重偏见的相关性。
这项横断面研究基于一份自填式在线问卷，通过方便的滚雪球抽样方法招募参与者。使用一种新开发的结构，即迷你健康信念和对GLP-1药物态度量表（mini-HBAGS），以及一种评估肥胖/超重偏见（OOB）的新量表，来评估对Mounjaro和Ozempic的态度。通过内容效度、主成分分析（PCA）和克朗巴哈α系数来评估新结构的效度。
该研究包括413名参与者，主要来自科威特（32.8%）、埃及（20.9%）、沙特阿拉伯（18.8%）和约旦（15.4%）。对Mounjaro和Ozempic的熟悉程度很高（83.6%），17.2%的人推荐使用。体重管理药物的使用率为14.0%，其中Mounjaro和Ozempic的使用率为5.9%。在熟悉Mounjaro和Ozempic的参与者中，OOB平均得分为3.83±0.62（范围：1.00-5.00），表明达成共识，而迷你H-BAGS的平均得分为2.70±0.716（范围：1.00-5.00），表明态度略显不利。主成分分析确定了感知到的益处和障碍以及主观规范和态度，是对Mounjaro和Ozempic态度的关键决定因素。
这项研究揭示了阿拉伯国家医疗保健专业人员和学生对Mounjaro和Ozempic的态度略显消极。观察到的消极态度可能反映了对这些药物的副作用、成本和可及性的担忧。研究结果强调了在阿拉伯国家开展针对性教育的必要性，以解决肥胖偏见问题，并鼓励对GLP-1药物用于体重管理的益处和风险进行平衡评估。
